Клиническое исследование применения кальция полистиролсульфоната для коррекции гиперкалемии у пациентов на программном гемодиализе
- Авторы: Шутов Е.В1,2, Котлярова Г.В1, Лысенко К.М1, Федоров Д.В1
-
Учреждения:
- ГБУЗ «Городская клиническая больница им. С.П. Боткина» ДЗ г. Москвы
- ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» М3 РФ
- Выпуск: № 1 (2019)
- Страницы: 22-27
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/273170
- DOI: https://doi.org/10.18565/nephrology.2019.1.22-27
- ID: 273170
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Е. В Шутов
ГБУЗ «Городская клиническая больница им. С.П. Боткина» ДЗ г. Москвы; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» М3 РФ
Email: shutov_e_v@mail.ru
д.м.н., зав. отделением нефрологии № 12; профессор кафедры нефрологии и гемодиализа Москва, Россия
Г. В Котлярова
ГБУЗ «Городская клиническая больница им. С.П. Боткина» ДЗ г. Москвык.м.н., врач-нефролог отделения нефрологии Москва, Россия
К. М Лысенко
ГБУЗ «Городская клиническая больница им. С.П. Боткина» ДЗ г. Москвыврач-нефролог отделения нефрологии № 12 Москва, Россия
Д. В Федоров
ГБУЗ «Городская клиническая больница им. С.П. Боткина» ДЗ г. Москвыврач-нефролог отделения нефрологии № 12 Москва, Россия
Список литературы
- Mushiyakh Y., Dangaria H., Qavi S. Treatment and pathogenesis of acute hyperkalemia. J. Community Hosp. Intern. Med. Perspect. 2011; 1(4).
- Lehnhardt A, Kemper M.J. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr. Nephrol. 2011; 26: 377-384.
- Crawford A.H. Hyperkalemia: recognition and management of a critical electrolyte disturbance. J. Infus. Nurs. 2014; 37: 167-175. doi: 10.1097/NAN.0000000000000036.
- Jain N., Kotla S., Little B.B. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am. J. Cardiol. 2012; 109: 1510-1513. doi: 10.1016/j.amjcard.2012.01.367.
- McMahon G.M., Mendu M.L., Gibbons F.K., Christopher K.B. Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. 2012; 38: 1834-1842. doi: 10.1007/s00134-012-2636-7.
- Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J. Am. Soc. Nephrol. 1995; 6: 1134-1142.
- Acker C.G., Johnson J.P., Palevsky P.M., Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch. Intern. Med. 1998; 158: 917-924.
- Khanagavi J., Gupta T., Aronow W.S. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes. Arch. Med. Sci. 2014; 10: 251-257. doi: 10.5114/aoms.2014.42577.
- Noize P., Bagheri H., Durrieu G. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharma Coepidemiol. Drug Saf. 2011; 20: 747-753. doi: 10.1002/pds.2128.
- Nyirenda M.J., Tang J.I., Padfield PL., Seckl J.R. Hyperkalaemia. BMJ. 2009; 339: b4114.
- Einhorn L.M., Zhan M., Hsu V.D. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 2009; 169: 1156-1162. doi: 10.1001/archinternmed.2009.132.
- Hayes J., Kalantar-Zadeh K., Lu J.L. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin. Pract. 2012; 120: c8-c16. doi: 10.1159/000329511.
- Kovesdy C.P, Regidor D.L., Mehrotra R. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2007; 2: 999-1007.
- Pitt B., Collins A.J., Reaven N. Effect of cardiovascular comorbidities on the mortality risk associated with serum potassium. Circulation. 2014; 130(2): A13320-A13320.
- Torlen K., Kalantar-Zadeh K., Molnar M.Z. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin. J. Am. Soc. Nephrol. 2012; 7: 1272-1284. doi: 10.2215/CJN.00960112.
- Rastegar A., Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad. Med. J. 2001 Dec; 77(914): 759-64. Erratum in: Postgrad. Med. J. 2002; 78(916): 126.
- Kovesdy C.P. Management of hyperkalaemia in chronic kidney disease. Nat. Rev. Nephrol. 2014; 10(11): 653-662. doi: 10.1038/nrneph.2014.168.
- Weiner I.D., Wingo C.S. Hyperkalemia: a potential silent killer. J. Am. Soc. Nephrol. 1998; 9(8): 1535-1543.
- Hollander-Rodriguez J.C., Calvert J.F. Jr. Hyperkalemia. Am. Fam. Physician. 2006; 73(2): 283-290.
- Widimisky P. Hypokalemia and the heart. E-J. Cardiol. Pract. 2008; 7: 9-12.
- An J.N., Lee J.P., Jeon H.J., Kim H., Oh Y.K., Kim Y.S., Lim C.S. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit. Care. 2012; 16: R225. doi: 10.1186/cc11872.
- Herzog C.A., Mangrum J.M., Passman R. Sudden cardiac death and dialysis patients. Semin. Dial. 2008; 21(4): 300-307.
- Foley R.N., Gilbertson D.T., Murray T., Collins A.J. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 2011; 365(12): 1099-1107. doi: 10.1056/NEJMoa1103313.
- Bleyer A.J., Hartman J., Brannon P.C., Reeves-Daniel A., Satko S.G., Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006; 69(12): 2268-2273.
- Perazella M.A., Mahnensmith R.L. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J. Gen. Intern. Med. 1997; 12(10): 646-656.
- Sonal Korgaonkar, Anca Tilea, Brenda W., et al. Serum Potassium and Outcomes in CKD: Insights from the RRI-CKD Cohort Study Clin. J. Am. Soc. Nephrol. 2010; 5(5): 762-769.
- Sacchetti A., Stuccio N., Panebianco P., Torres M., et al. ED hemodialysis for treatment of renal failure emergencies. Am. J. Emerg. Med.1999; 17(3): 305-307.
- Lepage L., Dufour A.C., Doiron J., et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin. J. Am. Soc. Nephrol. 2015; 10: 2136-2142.
- Nasir K., Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: A comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J. Ayub. Med. College, Abbottabad: JAMC. 2014; 26: 455-458.
- Gruy Kapral C., Emmett M., Santa Ana C.A., Porter J.L., Fordtran J.S., Fine K.D. Effect of single dose resin cathartic therapy on serum potassium concentration in patients with end stage renal disease. J. Am. Soc. Nephrol. 1998; 9: 1924-1930.
- Sterns R.H., Rojas M., Bernstein P., Chennupati S. Ion Exchange resins for the treatment of hyperkalemia: Are they safe and effective? J. Am. Soc. Nephrol. 2010; 21: 733-735.
- Scherr L., Ogden D.A., Mead A.W., Spritz N., Rubin A.L. Management of hyperkalemia with a cation exchange resin. N. Engl. J.Med. 1961; 264: 115-119.
- Noureddine L., Dixon B.S. Complications and management of hyperkalemia: Implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer. Clin. Invest. 2015; 5: 805-823.
- Betts K.A., Woolley J.M., Fan Mu, et al. The cost of hyperkalemia in the United States Kidney Int. Rep. 2018; 3(2): 385-393. doi: 10.1080/03007995.2018.1433141.
Дополнительные файлы
![](/img/style/loading.gif)